Patents by Inventor Michael S. Bowsher

Michael S. Bowsher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20240374598
    Abstract: Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Application
    Filed: July 12, 2024
    Publication date: November 14, 2024
    Inventors: Michael S. Bowsher, Eric P. Gillis, Christiana Iwuagwu, B. Narasimhulu Naidu, Kyle E. Parcella, Manoj Patel, Kevin M. Peese
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20230013823
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: October 2, 2020
    Publication date: January 19, 2023
    Inventors: Michael S. BOWSHER, Eric P. GILLIS, B. Narasimhulu NAIDU, Kyle E PARCELLA, Manoj PATEL
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20220389007
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: September 29, 2020
    Publication date: December 8, 2022
    Inventors: Michael S. BOWSHER, Eric P. GILLIS, Christiana IWUAGWU, B Narasimhulu NAIDU, Kyle E. PARCELLA, Manoj PATEL
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20220370451
    Abstract: Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Application
    Filed: October 6, 2020
    Publication date: November 24, 2022
    Inventors: Michael S. BOWSHER, Eric P. GILLIS, Kyle E. PARCELLA, Christiana IWUAGWU
  • 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
    Patent number: 11505543
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: November 22, 2022
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Makonen Belema, John A. Bender, David B. Frennesson, Eric P. Gillis, Christiana Iwuagwu, John F. Kadow, B. Narasimhulu Naidu, Kyle E. Parcella, Kevin M. Peese, Ramkumar Rajamani, Mark G. Saulnier, Alan Xiangdong Wang, Manoj Patel, Michael S. Bowsher
  • QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20210403465
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: October 28, 2019
    Publication date: December 30, 2021
    Inventors: Eric P. GILLIS, Kyle E. PARCELLA, Michael S. BOWSHER
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20210395262
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Application
    Filed: October 22, 2019
    Publication date: December 23, 2021
    Inventors: Eric P. GILLIS, Kyle E. PARCELLA, Manoj PATEL, Christiana IWUAGWU, Michael S. BOWSHER, Alan Xiangdong WANG
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20210395248
    Abstract: Compounds of Formula I, and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: November 4, 2019
    Publication date: December 23, 2021
    Inventors: Michael S. BOWSHER, Eric P. GILLIS, Christiana IWUAGWU, Kyle E. PARCELLA, Kevin M. PEESE
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20210379071
    Abstract: Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 9, 2021
    Inventors: Michael S. BOWSHER, Eric P. GILLIS, Christiana IWUAGWU, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Manoj PATEL, Kevin M. PEESE
  • 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20210024503
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: April 11, 2019
    Publication date: January 28, 2021
    Inventors: Makonen BELEMA, John A. BENDER, David B. FRENNESSON, Eric P. GILLIS, Christiana IWUAGWU, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Ramkumar RAJAMANI, Mark G. SAULNIER, Alan Xiangdong WANG, Manoj PATEL, Michael S. BOWSHER
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20200055839
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: January 2, 2018
    Publication date: February 20, 2020
    Inventors: Makonen BELEMA, Michael S. BOWSHER, Jeffrey A. DESKUS, Kyle J. EASTMAN, Eric P. GILLIS, David B. FRENNESSON, Christiana IWUAGWU, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Mark G. SAULNIER, Prasanna SIVAPRAKASAM
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 10538555
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: January 21, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A. M. Cornelius
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20200016136
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: January 2, 2018
    Publication date: January 16, 2020
    Inventors: Michael S. BOWSHER, Jeffrey DESKUS, Kyle J. EASTMAN, Eric P. GILLIS, David B. FRENNESSON, Christiana IWUAGWU, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Mark G. SAULNIER, Prasanna SIVAPRAKASAM
  • Immunomodulators
    Patent number: 10358463
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: July 23, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Michael S. Bowsher, Eric P. Gillis, Eric Mull, Qian Zhao, Li-Qiang Sun, David R. Langley, Paul Michael Scola
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 9879046
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: January 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Patrick C. Reid, Paul Michael Scola
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20170369530
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: August 9, 2017
    Publication date: December 28, 2017
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 9850283
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • IMMUNOMODULATORS
    Publication number: 20170283463
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 5, 2017
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Michael S. Bowsher, Eric P. Gillis, Eric Mull, Qian Zhao, Li-Qiang Sun, David R. Langley, Paul Michael Scola
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20170260237
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: September 11, 2014
    Publication date: September 14, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A.M. Cornelius
  • Hepatitis C virus inhibitors
    Patent number: 9598433
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric P. Gillis, Eric Mull, Michael S. Bowsher, Qian Zhao, Paul Michael Scola